Abdul Abou-Samra
Tanzania
Research Article
Sitagliptin Suppresses Active Ghrelin in Patients with Diabetes
Author(s): Berhane Seyoum, Alemu Fite and Abdul Abou-SamraBerhane Seyoum, Alemu Fite and Abdul Abou-Samra
Ghrelin is an appetite-stimulating hormone mainly produced by the stomach. Circulating levels of ghrelin increase in fasting sates and fall following meal. Sitagliptin is an orally available new class of anti-diabetic drug that inhibits dipeptidyl peptidase-4 (DPP-4) leading to 2-3 fold increase in the serum concentration of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). This study was performed to determine the effects of sitagliptin on circulating levels of ghrelin in control subjects (N=15) and diabetic patients (N=46). The diabetic patients were treated with sitagliptin (N=15), metformin (N=16) or combination of sitagliptin and metformin (N=15) for one week. Serum concentrations of total and active ghrelin were determined immediately before and 2 hours after meal challenge. The tests were repeated amon.. View More»
